These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38402331)

  • 1. Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Cui Y; Yao J; Qiu X; Guo C; Kong D; Dong J; Liao L
    Diabetes Ther; 2024 Apr; 15(4):781-799. PubMed ID: 38402331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis.
    Guan R; Yang Q; Yang X; Du W; Li X; Ma G
    Front Pharmacol; 2022; 13():998816. PubMed ID: 36313305
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis.
    Tang Y; Zhang L; Zeng Y; Wang X; Zhang M
    Front Pharmacol; 2022; 13():1016639. PubMed ID: 36569320
    [No Abstract]   [Full Text] [Related]  

  • 5. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials.
    Cai W; Zhang R; Yao Y; Wu Q; Zhang J
    Front Public Health; 2024; 12():1277113. PubMed ID: 38356942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials.
    Permana H; Yanto TA; Hariyanto TI
    Diabetes Metab Syndr; 2022 Nov; 16(11):102640. PubMed ID: 36274410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss efficiency and safety of tirzepatide: A Systematic review.
    Lin F; Yu B; Ling B; Lv G; Shang H; Zhao X; Jie X; Chen J; Li Y
    PLoS One; 2023; 18(5):e0285197. PubMed ID: 37141329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.
    Bhagavathula AS; Vidyasagar K; Tesfaye W
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Khan Z; Naeem MO; Khan SK; Khan F; Abdullah M; Attique I; Dur Muhammad S; Amin A
    Cureus; 2023 Aug; 15(8):e44314. PubMed ID: 37779743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.
    Ding Y; Shi Y; Guan R; Yan S; Liu H; Wang Z; Li J; Wang T; Cai W; Ma G
    Pharmacol Res; 2024 Jan; 199():107031. PubMed ID: 38061595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
    Zaazouee MS; Hamdallah A; Helmy SK; Hasabo EA; Sayed AK; Gbreel MI; Elmegeed AA; Aladwan H; Elshanbary AA; Abdel-Aziz W; Elshahawy IM; Rabie S; Elkady S; Ali AS; Ragab KM; Nourelden AZ
    Diabetes Metab Syndr; 2022 Jun; 16(6):102511. PubMed ID: 35623229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.
    Bradley CL; McMillin SM; Hwang AY; Sherrill CH
    Ann Pharmacother; 2023 Jul; 57(7):822-836. PubMed ID: 36367094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects.
    Jensen TL; Brønden A; Karstoft K; Sonne DP; Christensen MB
    Patient Prefer Adherence; 2024; 18():373-382. PubMed ID: 38352159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program.
    Frías JP; Galindo RJ; Wang H; Malik RE; Chivukula KK; Maldonado JM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):557-568. PubMed ID: 37602701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.